Levetiracetam Tad (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. By stabilising neuronal firing and decreasing excessive excitability, the drug limits the spread of seizure activity across the brain.

The specific dose of Levetiracetam Tad is determined by the prescribing clinician based on the patient’s age, weight, renal function, and seizure type. Dosage adjustments are made to achieve optimal seizure control while minimizing side effects.

Levetiracetam’s pregnancy safety category is not definitively established. Healthcare providers weigh potential benefits against unknown risks when prescribing to pregnant or nursing women. Consultation with a specialist is recommended before use in these populations.

To request Levetiracetam Tad, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older agents such as carbamazepine or phenytoin, levetiracetam has a simpler pharmacokinetic profile, fewer drug‑enzyme interactions, and is generally well tolerated. However, individual response varies, and clinicians may choose therapy based on seizure type, comorbidities and patient preference.

Levetiracetam Tad should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Levetiracetam Tad is taken orally, usually with or without food, as directed by the prescriber. The tablets are swallowed whole with water and should be taken at the same times each day to maintain consistent blood levels.

Serious risks include severe psychiatric reactions such as depression or suicidal thoughts, rare skin disorders like Stevens‑Johnson syndrome, blood dyscrasias, and hypersensitivity reactions. Patients should report any unusual mood changes, rash, or signs of infection promptly.

Levetiracetam Tad is contraindicated in patients with known hypersensitivity to levetiracetam or any of its excipients. Caution is advised for individuals with severe renal impairment, uncontrolled psychiatric illness, or those who are pregnant without a clear benefit‑risk assessment.